STOCK TITAN

Werewolf Therapeutics Inc - HOWL STOCK NEWS

Welcome to our dedicated news page for Werewolf Therapeutics (Ticker: HOWL), a resource for investors and traders seeking the latest updates and insights on Werewolf Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Werewolf Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Werewolf Therapeutics's position in the market.

Rhea-AI Summary
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) announces the acceptance of an abstract for the presentation of its ongoing Phase 1/1b study of WTX-124 at the 2024 ASCO Annual Meeting. The study focuses on the IL-2 prodrug WTX-124 in patients with advanced solid tumors after checkpoint inhibitor therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
none
-
Rhea-AI Summary
Werewolf Therapeutics presents first preclinical data on IL-10 INDUKINE molecules as a potential therapy for Inflammatory Bowel Disease at the AAI Annual Meeting. The company leverages its PREDATOR™ platform for this novel approach, aiming to address the clear need for additional treatment options in IBD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.75%
Tags
-
Rhea-AI Summary
Werewolf Therapeutics, Inc. presents promising preclinical data on WTX-518 and WTX-712 at AACR Annual Meeting. WTX-518 shows tumor regression by resisting IL-18BP suppression, while WTX-712 activates tumor-specific T lymphocytes. Both candidates demonstrate potent immunotherapeutic effects in preclinical models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.12%
Tags
Rhea-AI Summary
Werewolf Therapeutics, Inc. announces the expansion of its INDUKINE™ molecules into immunology targets beyond oncology, specifically in the treatment of inflammatory bowel disease. The company will present data at IMMUNOLOGYTM 2024, showcasing the potential of their PREDATOR protein engineering technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
conferences
-
Rhea-AI Summary
Werewolf Therapeutics, Inc. (HOWL) provides a business update and financial results for Q4 and full year 2023. The company plans to present additional clinical data from WTX-124 and WTX-330 in 2024. The updated cash guidance ensures funding through at least Q2 2025. Financially, collaboration revenue decreased in Q4 2023 compared to 2022, while research and development expenses decreased. Net loss also decreased for both Q4 and full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.98%
Tags
-
Rhea-AI Summary
Werewolf Therapeutics, Inc. (HOWL) announces participation in Leerink Partners Global Biopharma Conference. Daniel J. Hicklin, Ph.D., and Randi Isaacs, M.D. to discuss innovative cancer therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.93%
Tags
conferences
Rhea-AI Summary
Werewolf Therapeutics, Inc. (HOWL) announces abstracts for poster presentations at AACR Annual Meeting 2024, showcasing innovative conditionally activated therapeutics for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.93%
Tags
conferences
-
Rhea-AI Summary
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) provided a business update, outlining strategic priorities for 2024. The company plans to prioritize the development of clinical assets WTX-124 and WTX-330, with key updates anticipated in 2024. They also aim to progress preclinical programs, apply their PREDATOR™ platform for non-core opportunities, and maintain disciplined spend to optimize cash runway. The updated cash guidance provides runway through at least the first quarter of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.85%
Tags
none
-
Rhea-AI Summary
Werewolf Therapeutics, Inc. (Nasdaq: HOWL) announced the appointment of Michael B. Atkins, M.D., a world-renowned oncologist and clinical researcher, to its Board of Directors. Dr. Atkins brings over 30 years of experience in translational and clinical research, specializing in melanoma, kidney cancer, and cancer immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.1%
Tags
management
Rhea-AI Summary
Werewolf Therapeutics, Inc. (HOWL) announced that its President and CEO, Daniel J. Hicklin, Ph.D., and Chief Medical Officer, Randi Isaacs, M.D., will participate in a fireside chat at the Evercore ISI HealthCONx Conference. The company is known for developing conditionally activated therapeutics to stimulate the immune system for cancer treatment. The event will take place on November 29, 2023, in Miami, Florida, with a live webcast link available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
conferences
Werewolf Therapeutics Inc

Nasdaq:HOWL

HOWL Rankings

HOWL Stock Data

200.44M
22.58M
6.76%
73.87%
1.1%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Watertown

About HOWL

we are an immuno-oncology company advancing a pipeline of next generation, transformative cancer treatments.